methyl 6-methyl-2-oxo-4-(4'-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 6-methyl-2-oxo-4-(4'-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate
• 英文别名: Methyl 6-methyl-2-oxo-4-[4-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate；methyl 6-methyl-2-oxo-4-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-pyrimidine-5-carboxylate
• 化学式: C₁₄H₁₃F₃N₂O₃
• 分子量: 314.264
• InChiKey: CBVQPSUPCZGJOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  对三氟甲基苯甲醛 、 乙酰乙酸甲酯 、 尿素 在 copper(II) nitrate trihydrate 作用下， 以 neat (no solvent) 为溶剂， 以82%的产率得到methyl 6-methyl-2-oxo-4-(4'-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate
  参考文献：
  名称：

  二氢嘧啶酮：作为一类新型的β-葡萄糖醛酸苷酶抑制剂

  摘要：

  Dihydropyrimidones 1 - 37分别经由“一锅”根据通过利用铜公知的Biginelli反应三个组分反应而合成（NO 3）2 ·3H 2 O作为催化剂，并筛选它们的体外β葡萄糖醛酸酶抑制活性。值得一提的是，在活性分子中，化合物8（IC 50  = 28.16±.056μM），9（IC 50  = 18.16± 0.41μM ），10（IC 50  = 22.14±0.43μM），13（IC 50  = 34.16±0.65μM），14（IC 50  = 17.60±0.35μM），15（IC 50  = 15.19±0.30μM），16（IC 50  = 27.16±0.48μM），17（IC 50  = 48.16±1.06μM），22（IC 50  = 40.16±0.85μM），23（IC 50  = 44.16） ±  0.86μM ），24（IC 50 = 47.16±0

  DOI：

  10.1016/j.bmc.2016.06.002

文献信息

• Parallel synthesis of dihydropyrimidinones using Yb(III)-resin and polymer-supported scavengers under solvent-free conditions. A green chemistry approach to the Biginelli reaction
  作者：Alessandro Dondoni、Alessandro Massi

  DOI：10.1016/s0040-4039(01)01728-2

  日期：2001.11

  An efficient synthesis of an array of 3,4-dihydropyrimidin-2-(1H)-ones using solid-supported ytterbium(III) reagent from aldehydes, 1,3-dicarbonyl compounds and urea (Biginelli reaction) under solvent-free conditions is described. Purification of each member of the library was carried out using a cocktail of acid and basic polymer-supported scavengers

  在无溶剂的条件下，由醛，1,3-二羰基化合物和脲（Biginelli反应）使用固载（III）试剂高效合成3,4-二氢嘧啶-2-（1 H）-酮阵列描述。使用酸和碱性聚合物支持的清除剂的混合物对文库的每个成员进行纯化
• Dihydropyrimidones: As novel class of β-glucuronidase inhibitors
  作者：Farman Ali、Khalid Mohammed Khan、Uzma Salar、Sarosh Iqbal、Muhammad Taha、Nor Hadiani Ismail、Shahnaz Perveen、Abdul Wadood、Mehreen Ghufran、Basharat Ali

  DOI：10.1016/j.bmc.2016.06.002

  日期：2016.8

  Dihydropyrimidones 1–37 were synthesized via a ‘one-pot’ three component reaction according to well-known Biginelli reaction by utilizing Cu(NO3)2·3H2O as catalyst, and screened for their in vitro β-glucuronidase inhibitory activity. It is worth mentioning that amongst the active molecules, compounds 8 (IC50 = 28.16 ± .056 μM), 9 (IC50 = 18.16 ± 0.41 μM), 10 (IC50 = 22.14 ± 0.43 μM), 13 (IC50 = 34.16 ± 0

  Dihydropyrimidones 1 - 37分别经由“一锅”根据通过利用铜公知的Biginelli反应三个组分反应而合成（NO 3）2 ·3H 2 O作为催化剂，并筛选它们的体外β葡萄糖醛酸酶抑制活性。值得一提的是，在活性分子中，化合物8（IC 50  = 28.16±.056μM），9（IC 50  = 18.16± 0.41μM ），10（IC 50  = 22.14±0.43μM），13（IC 50  = 34.16±0.65μM），14（IC 50  = 17.60±0.35μM），15（IC 50  = 15.19±0.30μM），16（IC 50  = 27.16±0.48μM），17（IC 50  = 48.16±1.06μM），22（IC 50  = 40.16±0.85μM），23（IC 50  = 44.16） ±  0.86μM ），24（IC 50 = 47.16±0
• <p>In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against <em>Mycobacterium tuberculosis</em></p>
  作者：Katharigatta N Venugopala、Christophe Tratrat、Melendhran Pillay、Sandeep Chandrashekharappa、Omar Husham Ahmed Al-Attraqchi、Bandar E Aldhubiab、Mahesh Attimarad、Osama I Alwassil、Anroop B Nair、Nagaraja Sreeharsha、Rashmi Venugopala、Mohamed A Morsy、Michelyne Haroun、Hezekiel M Kumalo、Bharti Odhav、Koleka Mlisana

  DOI：10.2147/dddt.s228381

  日期：——

  Background and Purpose: Tuberculosis has been reported to be the worldwide leading cause of death resulting from a sole infectious agent. The emergence of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis has made the battle against the infection more difficult since most currently available therapeutic options are ineffective against these resistant strains. Therefore, novel molecules need to be developed to effectively treat tuberculosis disease. Preliminary docking studies revealed that tetrahydropyrimidinone derivatives have favorable interactions with the thymidylate kinase receptor. In the present investigation, we report the synthesis and the mycobacterial activity of several pyrimidinones and pyrimidinethiones as potential thymidylate kinase inhibitors.Methods: The title compounds (1a-d) and (2a-b) were synthesized by a one-pot three-component Biginelli reaction. They were subsequently characterized and used for whole-cell anti-TB screening against H37Rv and multidrug-resistant (MDR) strains of Mycobacterium tuberculosis (MTB) by the resazurin microplate assay (REMA) plate method. Molecular modeling was conducted using the Accelry's Discovery Studio 4.0 client program to explain the observed bioactivity of the compounds. The pharmacokinetic properties of the synthesized compounds were predicted and analyzed.Results: Of the compounds tested for anti-TB activity, pyrimidinone la and pyrimidinethione 2a displayed moderate activity against susceptible MTB H37Rv strains at 16 and 32 mu g/mL, respectively. Only compound 2a was observed to exert modest activity at 128 mu g/mL against MTB strains with cross-resistance to rifampicin and isoniazid. The presence of the trifluoromethyl group was essential to retain the inhibitory activity of compounds la and 2a. Molecular modeling studies of these compounds against thymidylate kinase targets demonstrated a positive correlation between the bioactivity and structure of the compounds. The in- silico ADME (absorption, distribution, metabolism, and excretion) prediction indicated favorable pharmaco - kinetic and drug-like properties for most compounds.Conclusion: Pyrimidinone 1a and pyrimidinethione 2a were identified as the leading compounds and can serve as a starting point to develop novel anti-TB therapeutic agents.